An author of a study in the May 2021 issue of The American Journal of Managed Care® describes how the COVID-19 pandemic, the aging of America, and already-existing workforce shortages will further threaten the dual-eligible population unless policy makers reform scope-of-practice laws.
Triple forces are combining to create a crisis for the nation’s dual-eligible beneficiaries—that is, individuals who are covered under both Medicare and Medicaid. They tend to have multiple, chronic, costly medical conditions and have very low incomes.
In the May issue of The American Journal of Managed Care®, Wendy Y. Xu, PhD; Sheldon M. Retchin, MD, MSPH; and Peter Buerhaus, PhD, RN, published a study showing how states with the most restrictive scope-of-practice laws have an inadequate supply of primary care clinicians to serve areas with a high concentration of these vulnerable beneficiaries.
In this episode of Managed Care Cast, Xu describes how the COVID-19 pandemic, the aging of America, and already-existing workforce shortages will further threaten this population unless policy makers reform scope-of-practice laws.
Listen above or through one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More